

Contents

List of Contributors, ix

Preface, xvi

Acknowledgements, xx

PART I Introduction, 1

- 1** What is Pharmacoepidemiology?, 3
Brian L. Strom
- 2** Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies, 23
Jeffrey S. Barrett and Athena F. Zuppa
- 3** Basic Principles of Clinical Epidemiology Relevant to Pharmacoepidemiologic Studies, 38
Brian L. Strom
- 4** Sample Size Considerations for Pharmacoepidemiologic Studies, 52
Brian L. Strom
- 5** When Should One Perform Pharmacoepidemiologic Studies?, 62
Brian L. Strom

PART II The Role of Pharmacoepidemiology in Different Sectors, 71

- 6** The Role of Pharmacoepidemiology in the Health-Care System and Academia, 73
Jerry Avorn
- 7** The Role of Pharmacoepidemiology in Industry, 84
Jingping Mo, Nicolle M. Gatto, Rachel E. Sobel, and Robert F. Reynolds
- 8** The Role of Pharmacoepidemiology in Regulatory Agencies, 107
Gerald J. Dal Pan and Peter Arlett
- 9** Pharmacoepidemiology and the Law, 117
Aaron S. Kesselheim

PART III Sources of Data for Pharmacoepidemiologic Studies, 135

Section A: Spontaneous Reporting

- 10** Postmarketing Spontaneous Pharmacovigilance Reporting Systems, 137
Gerald J. Dal Pan, Marie Lindquist, and Kate Gelperin

Section B: Automated Data Systems

- 11** Overview of Automated Databases in Pharmacoepidemiology, 158
Brian L. Strom
- 12** Health Maintenance Organizations/Health Plans, 163
Susan E. Andrade, Marsha A. Raebel, Denise Boudreau, Robert L. Davis, Katherine Haffenreffer, Pamala A. Pawloski, Sengwee Toh, and Richard Platt
- 13** Commercial Insurance Databases, 189
John Seeger and Gregory W. Daniel
- 14** US Government Claims Databases, 209
Sean Hennessy, Cristin Palumbo Freeman, and Francesca Cunningham
- 15** Medical Record Databases, 224
Alexis Ogdie, Sinéad M. Langan, John Parkinson, Hassy Dattani, Karel Kostev, and Joel M. Gelfand
- 16** In-hospital Databases, 244
Brian T. Fisher, Peter K. Lindenauer, and Chris Feudtner
- 17** Canadian Provincial Databases, 259
Yola Moride and Colleen J. Metge
- 18** Pharmacy-based Medical Record Linkage Systems, 270
Ron M.C. Herings and Lars Pedersen

Section C: Ad Hoc Studies—Ongoing Systems for Pharmacoepidemiologic Studies

- 19** Case–Control Surveillance, 287
Lynn Rosenberg, Patricia F. Coogan, and Julie R. Palmer
- 20** Prescription–Event Monitoring, 301
Deborah Layton and Saad A.W. Shakir
- 21** Registries, 331
Nancy A. Dreyer and Priscilla Velentgas

Section D: Ad Hoc Studies—De Novo Studies

- 22** Field Studies, 347
David W. Kaufman

Section E: Choosing Among the Available Alternatives

- 23** How Should One Perform Pharmacoepidemiologic Studies?
Choosing Among the Available Alternatives, 364
Brian L. Strom

PART IV Selected Special Applications of Pharmacoepidemiology, 377

- 24** Studies of Drug Utilization, 379
David Lee and Ulf Bergman
- 25** Evaluating and Improving Physician Prescribing, 402
Sumit R. Majumdar, Helene Levens Lipton, and Stephen B. Soumerai

- 26** Pharmacoepidemiologic Studies of Vaccine Safety, 423
Robert T. Chen, Jason M. Glanz, and Claudia Vellozzi
- 27** Epidemiologic Studies of Medical Devices: Methodologic Considerations for Implantable Devices, 469
Danica Marinac-Dabic, Sharon-Lise Normand, Art Sedrakyan, and Thomas Gross
- 28** Studies of Drug-Induced Birth Defects, 487
Allen A. Mitchell
- 29** Risk Management, 505
Gerald J. Dal Pan, Stella Blackburn, and Claudia Karwoski
- 30** FDA's Sentinel Initiative: Active Surveillance to Identify Safety Signals, 534
Judith A. Racoosin, Melissa A. Robb, Rachel E. Sherman, and Janet Woodcock
- 31** Pharmacoepidemiology and Pharmaceutical Reimbursement Policy, 555
Mitchell Levine and Jacques LeLorier
- 32** Comparative Effectiveness Research, 561
Brian L. Strom, Rita Schinnar, and Sean Hennessy

PART V Selected Special Methodologic Issues in Pharmacoepidemiology, 581

- 33** Assessing Causality of Case Reports of Suspected Adverse Events, 583
Judith K. Jones
- 34** Molecular Pharmacoepidemiology, 601
Stephen E. Kimmel, Hubert G. Leufkens, and Timothy R. Rebbeck
- 35** Bioethical Issues in Pharmacoepidemiologic Research, 623
Antoine C. El Khoury, Jason Karlawish, Elizabeth Andrews, and Arthur Caplan
- 36** The Use of Randomized Controlled Trials for Pharmacoepidemiologic Studies, 640
Samuel M. Lesko and Allen A. Mitchell
- 37** The Use of Pharmacoepidemiology to Study Beneficial Drug Effects, 655
Brian L. Strom and Kenneth L. Melmon
- 38** Pharmacoeconomics: Economic Evaluation of Pharmaceuticals, 678
Kevin A. Schulman, Henry A. Glick, Daniel Polsky, and Shelby D. Reed
- 39** Using Quality-of-Life Measurements in Pharmacoepidemiologic Research, 709
Holger Schünemann, Bradley C. Johnston, Roman Jaeschke, and Gordon H. Guyatt
- 40** The Use of Meta-analysis in Pharmacoepidemiology, 723
Jesse A. Berlin, M. Soledad Cepeda, and Carin J. Kim
- 41** Validity of Pharmacoepidemiologic Drug and Diagnosis Data, 757
Suzanne L. West, Mary Elizabeth Ritchey, and Charles Poole
- 42** Studies of Medication Adherence, 795
Trisha Acri and Robert Gross

- 43** Risk Evaluation and Communication, 810
Susan J. Blalock and Betsy L. Sleath
- 44** Studying Effects of Antibiotics, 827
Darren R. Linkin and Ebbing Lautenbach
- 45** The Pharmacoepidemiology of Medication Errors, 840
Hanna M. Seidling and David W. Bates
- 46** Sequential Statistical Methods for Prospective
Postmarketing Safety Surveillance, 852
Martin Kulldorff
- 47** Advanced Approaches to Controlling Confounding
in Pharmacoepidemiologic Studies, 868
Sebastian Schneeweiss and Samy Suissa

PART VI Conclusion, 893

- 48** The Future of Pharmacoepidemiology, 895
Brian L. Strom, Stephen E. Kimmel, and Sean Hennessy
- Appendix A: Sample Size Tables, 904
- Appendix B: Glossary, 921

Index, 931